| Name | Title | Contact Details |
|---|
Create the most delightful experiences for our guests. We believe we can positively change the way people think about alternative lodging. The process begins by seeking out high-quality homes with modern spaces and prime locations, to ensure our designers can bring out the natural beauty of each property and to give you an authentic travel experience. We deck out each Domio with curated furniture, accessories and artwork to create a distinguished level of style and comfort, and provide round-the-clock concierge services for your convenience. With Domio, feel at home anywhere in the world.
National Diagnostics is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BASi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. We provide world-class research to the global pharmaceutical industry. Our services include Preclinical Toxicology, Early In Vivo PK, Bioanalysis and a full range of pharmaceutical analysis services. BASi also manufactures innovative scientific instruments including the Culex® Automated In Vivo Sampling System which can collect blood, bile, microdialysates, activity behavior, telemetry data and more from awake, freely-moving subjects. We are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on time.
Nobest Inc is a Garden Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.